

## Melanoma / Renal Cell Carcinoma

---

Reference Number: F4982  
Date of Response: 31/10/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- Avelumab + Axitinib **≤5 patients**
- Axitinib **≤5 patients**
- Cabozantinib **11 patients**
- Everolimus **≤5 patients**
- Lenvatinib + Everolimus **0 patients**
- Nivolumab **10 patients**
- Nivolumab + Cabozantinib **0 patients**
- Nivolumab + Ipilimumab **≤5 patients**
- Pazopanib **≤5 patients**
- Pembrolizumab + Axitinib **0 patients**
- Pembrolizumab + Lenvatinib **0 patients**
- Pembrolizumab monotherapy **0 patients**
- Radiotherapy only **0 patients**
- Sunitinib **8 patients**
- Temsirolimus **0 patients**
- Tivozanib **0 patients**
- Other active systemic anti-cancer therapy **0 patients**
- Palliative care only **≤5 patients**

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- Cobimetinib **0 patients**
- Dabrafenib **≤5 patients**
- Dabrafenib AND Trametinib **8 patients**
- Dacarbazine **0 patients**
- Encorafenib AND Binimetinib **≤5 patients**
- Ipilimumab **≤5 patients**
- Ipilimumab AND Nivolumab **6 patients**
- Nivolumab **≤5 patients**
- Pembrolizumab **50 patients**
- Trametinib **0 patients**
- Vemurafenib **0 patients**
- Vemurafenib AND Cobimetinib **0 patients**
- Other active systemic anti-cancer therapy **6 patients**
- Palliative care only **0 patients**

≤5. In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.